Future University In Egypt (FUE)
Future University is one of most promising private universities in Egypt. Through excellence in teaching, research and service, Future University strives to provide a comprehensive, high-quality education that prepares our graduates to be future leaders.
mainLogo
Altagamoa Al Khames, Main centre of town, end of 90th Street
New Cairo
Egypt

Eman Elmokadem

Basic information

Name : Eman Elmokadem
Title: Lecturer
Google Schoolar Link
Personal Info: Eman Elmokadem ,Lecturer at Pharmacy Practice and Clinical Pharmacy department, she got her Ph.D. degree from Ain Shams University

Education

Certificate Major University Year
PhD Clinical Pharmacy 2021
Masters Clinical Pharamacy 2015
Bachelor 2006

Researches /Publications

The efficacy and safety of itopride in feeding intolerance of critically ill patients receiving enteral nutrition: a randomized, double-blind study - 01/0

EMAN MOHAMED ABDELLATIF ELMOKADEM

Radwa Maher EL Borolossy, Ahmed M. Bassiouny, Maha Gamil Hanna, Ebtissam Abdel Ghaffar Darweesh & Nagwa A. Sabri

01/03/2021

Background Enteral feeding intolerance (EFI) is a frequent problem in the Intensive care unit (ICU) and is associated with poor clinical outcomes leading to worse prognosis in terms of mortality and ICU stay. Nowadays, prokinetic drugs are the mainstay of therapy in EFI. However, available prokinetics have uncertain efficacy and safety profiles. Itopride, is a prokinetic agent which is different and unique from the available prokinetics because of its dual mode of action as well as its tolerability and safety. The current study compared the efficacy and safety of Itopride against metoclopramide for EFI in critically ill patients. Moreover, it tested the utility and applicability of ultrasonography to measure gastric residual volume (GRV) in this population. Methods This randomized, double-blind study included 76 EFI patients who were randomly assigned to either Itopride or metoclopramide group. The primary outcome was to measure GRV by ultrasonography. Secondary outcomes included the percentage ratio of enteral feed volume, energy and protein received by patients over 7 days of treatment, ICU length of stay, safety parameters and occurrence of infectious complications or vomiting. Results Thirty-five patients of each group completed the study. At day 7, itopride significantly decreased GRV compared with metoclopramide group (p = 0.001). Moreover, there was a significant increase in the ratios of received enteral nutrition feed volume, calories, and protein after the one-week therapy in the itopride group more than the metoclopramide group (p = 0.001), (p = 0.002), (p = 0.01), respectively and there were no differences in any secondary outcomes or adverse events between the two groups. Conclusion In critically ill patients with EFI, itopride was well tolerated with superior efficacy to metoclopramide. In addition, we demonstrated that ultrasonography is a simple, non-invasive, inexpensive, and undemanding method for GRV measurements and can offer reliable assessments in the gastric emptying modality. Trial registration The trial was registered in ClinicalTrials.gov (NCT03698292). Date: October 5, 2018

Download PDF
CLINICAL OUTCOME STUDY OF CRITICALLY-ILL SEPTIC PATIENTS GIVEN TAURINE SUPPLEMENTED ENTERAL NUTRITION - 01/0

EMAN MOHAMED ABDELLATIF ELMOKADEM

EM Elmokadem, NA Sabri, TA Roshdy, AM Hasanin

01/08/2015

Sepsis is a significant public health concern and the main cause of death in surgical intensive care units (ICU). Patients with sepsis have features consistent with immunosuppression. Taurine is rapidly emerging as one of the more interesting amines which has been reported to have immune-modulatory effect through its action on cytokines. To determine the effect of using Immune-enhancing enteral nutritional feed containing taurine compared to standard enteral nutritional feed on clinical outcomes of ICU septic

Download PDF

Follow us on

Visit the Faculty

ADS